On the third episode of "Real Talk, Real-World Data", Joshua is joined by Ana Mingorance. Since she was a child, Ana has had the goal of curing a disease. She carried this with her into adulthood and sits down to share some insights she has taken away over her 13 years in the industry. Ana is the founder and CEO of Singularity Bio, a biotech startup with the mission to make all complex conditions treatable by developing treatment to induce specific cell states to fight diseases. Prior to this role, Ana was the Chief Development Officer at the Loulou Foundation and Scientific Director at the Dravet Syndrome Foundation in Spain. Ana has spent her career working to make patients a bigger part of drug discovery and drug development by supporting patient groups to be involved in R&D. She has also written a short titled "#ImpatientRevolution" that contains advice and tools for patient groups who are looking to be involved in drug development and clinical trials. The book is free to download and can be viewed here.
Ana and Joshua cover a wide variety of topics that range from the challenges and best practices for working with multiple pharma companies on the same study, how patient leadership will evolve to become more important in the future, how to maximize user retention in a registry, the role real-world data amplifying the patients voice and much more. This is the third installment in our series about rare epilepsy and is in support of CDKL5 awareness month. Check out our latest episode and be part of the conversation! Stay up to date on new podcast release dates and highlight videos on our social media channels below.
Facebook
LinkedIn
Twitter